QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)

Talaris Therapeutics Stock Price, News & Analysis (NASDAQ:TALS)

$18.97
-0.03 (-0.16%)
(As of 12/5/2023 ET)
Compare
Today's Range
$18.59
$19.26
50-Day Range
$2.59
$19.50
52-Week Range
$0.89
$27.95
Volume
76,969 shs
Average Volume
386,531 shs
Market Capitalization
$811.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

TALS stock logo

About Talaris Therapeutics Stock (NASDAQ:TALS)

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

TALS Stock Price History

TALS Stock News Headlines

Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR
See More Headlines
Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Ex-Dividend for 10/20 Dividend
10/20/2023
Dividend Payable
10/20/2023
Today
12/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TALS
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$12.00
Low Stock Price Target
$3.00
Potential Upside/Downside
-60.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-73,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.33 per share

Miscellaneous

Free Float
35,708,000
Market Cap
$811.23 million
Optionable
Not Optionable
Beta
2.18
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report














TALS Stock Analysis - Frequently Asked Questions

Should I buy or sell Talaris Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Talaris Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TALS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TALS, but not buy additional shares or sell existing shares.
View TALS analyst ratings
or view top-rated stocks.

What is Talaris Therapeutics' stock price target for 2024?

2 brokerages have issued 12-month price objectives for Talaris Therapeutics' shares. Their TALS share price targets range from $3.00 to $12.00. On average, they predict the company's share price to reach $7.50 in the next twelve months. This suggests that the stock has a possible downside of 60.5%.
View analysts price targets for TALS
or view top-rated stocks among Wall Street analysts.

How have TALS shares performed in 2023?

Talaris Therapeutics' stock was trading at $1.02 at the beginning of 2023. Since then, TALS stock has increased by 1,759.8% and is now trading at $18.97.
View the best growth stocks for 2023 here
.

How were Talaris Therapeutics' earnings last quarter?

Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03.

How often does Talaris Therapeutics pay dividends? What is the dividend yield for Talaris Therapeutics?

Talaris Therapeutics announced a dividend on Thursday, October 19th. Stockholders of record on Monday, October 16th will be paid a dividend of $1.5118 per share on Friday, October 20th. The ex-dividend date of this dividend is Friday, October 20th.
Read our dividend analysis for TALS
.

When did Talaris Therapeutics IPO?

(TALS) raised $150 million in an initial public offering on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO.

Who are Talaris Therapeutics' major shareholders?

Talaris Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include RA Capital Management L.P. (5.62%), Affinity Asset Advisors LLC (0.94%), Walleye Capital LLC (0.61%), Acuitas Investments LLC (0.45%), Marquette Asset Management LLC (0.09%) and Barclays PLC (0.04%). Insiders that own company stock include Francois Nader, Longitude Capital Partners Iii, Sandip Agarwala, Scott Requadt and Suzanne Ildstad.
View institutional ownership trends
.

How do I buy shares of Talaris Therapeutics?

Shares of TALS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TALS) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -